Oncology Nurse Edition Contact Us

Article

Editorial Inquiries:Anne Landry, Executive Editor Ph: 212-929-4624 Email: anne.landry@ubm.comContinuing Education: Marsha Peruo Ph: 201-984-6216 Email: marsha.peruo@cmellc.comEditorial Office: UBM Medica LLC 535 Connecticut Ave, Suite 300 Norwalk, CT 06854 Ph: 516-474-4766Publisher and Sales Contacts: Amy Birnbach Group Publisher Ph: 201-984-6265 Email: amy.birnbach@ubm.com Sarah Mifsud Account Manager Digital Media Ph: 203-523-7055 Email: sarah.mifsud@ubm.comWeb site Contact: Ian Ingram Web Editor Email: ian.ingram@ubm.com  

CONTACT US

Editorial Inquiries:
Anne Landry, Executive Editor
Ph: 212-929-4624
Email: anne.landry@ubm.comContinuing Education:
Marsha Peruo
Ph: 201-984-6216
Email: marsha.peruo@cmellc.comEditorial Office:
UBM Medica LLC
535 Connecticut Ave, Suite 300
Norwalk, CT 06854
Ph: 516-474-4766

Publisher and Sales Contacts:
Amy Birnbach
Group Publisher
Ph: 201-984-6265
Email: amy.birnbach@ubm.com

Sarah Mifsud
Account Manager
Digital Media
Ph: 203-523-7055
Email: sarah.mifsud@ubm.comWeb site Contact:
Ian Ingram
Web Editor
Email: ian.ingram@ubm.com
 

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content
Early Response Rates Noted With Elranatamab/Iberdomide in R/R Multiple Myeloma

Early Response Rates Noted With Elranatamab/Iberdomide in R/R Multiple Myeloma

Kristi Rosa
December 6th 2025
Article

Results from the MagnetisMM-30 trial showed early ORR data with elranatamab/iberdomide in R/R multiple myeloma.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Outcomes were comparable in the transplant-ineligible population, with KRd and VRd producing identical progression or death rates of 30%.

KRd Exhibits PFS Advantage vs VRd in Newly Diagnosed Multiple Myeloma

Jax DiEugenio
December 6th 2025
Article

Outcomes were comparable in the transplant-ineligible population, with KRd and VRd producing identical progression or death rates of 30%.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Cilta-Cel Exhibits Long-Term Survival in Standard-Risk R/R Multiple Myeloma

Chris Ryan
December 6th 2025
Article

The 2.5 year progression-free survival rate was 80.5% with cilta-cel for this population, suggesting a potential cure fraction.

Even among Black patients with sufficient social support for clinical trial enrollment, there is inequity related to accessing allogenic transplantation.

Poorer Outcomes Observed for Black Patients Undergoing Chemotherapy for AML

Bridget Hoyt
December 6th 2025
Article

Even among Black patients with sufficient social support for clinical trial enrollment, there is inequity related to accessing allogenic transplantation.